Using FLT3 Inhibitors to Treat Acute Myeloid Leukemia
A team of researchers at Mass General Cancer Center has reviewed the state of research surrounding FLT3 inhibitors.
Contact Information
Dr. Seth Wander is a medical oncologist at the Massachusetts General Hospital with a clinical and translational research interest in breast cancer and cancer genomics. Dr. Wander completed his undergraduate degree at Cornell University, where he studied Molecular and Cell Biology and graduated magna cum laude with distinction in research. He pursued his MD and PhD in Cancer Biology at the University of Miami. Dr. Wander completed his internship and residency in internal medicine at the Massachusetts General Hospital and his fellowship training in medical oncology at the Dana-Farber Cancer Institute and the Massachusetts General Hospital Cancer Center.
Dr. Wander is active in both the clinic and laboratory, where his research interests involve genomic mechanisms of resistance to targeted therapies in metastatic breast cancer. Dr. Wander has published more than forty peer-reviewed manuscripts focused on the emerging field of precision medicine and related topics in oncology. His research is focused on leveraging genetic and molecular sequencing results to understand how cancers become resistant to standard therapies in order to develop novel, personalized treatment strategies. He is an assistant professor of medicine at Harvard Medical School and remains engaged in teaching medical students, residents, and fellows. He was a recipient of the 2017 Dana-Farber Cancer Institute Wong Family Translational Research Award and a 2018 recipient of the Conquer Cancer Foundation/American Society of Clinical Oncology Young Investigator Award. Dr. Wander, as part of a multidisciplinary team, leads a variety of clinical trials focused on developing novel clinical strategies for patients with metastatic breast cancer and resistance to standard hormonal and targeted agents. He has presented educational sessions and original research both nationally and internationally related to drug resistance and the development of personalized treatment strategies for breast cancer.
Departments, Centers, & Programs:
Clinical Interests:
Treats:
Mass General Cancer Center
55 Fruit St.
Boston, MA 02114
Phone: 617-724-4000
Mass General Cancer Center in Danvers
102 Endicott St.
Danvers, MA 01923
Phone: 978-882-6060
Nantucket Cottage Hospital
57 Prospect St.
Nantucket, MA 02554
Phone: 508-825-8165
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
https://pubmed.ncbi.nlm.nih.gov/?term=Wander+S&sort=date
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.
A team of researchers at Mass General Cancer Center has reviewed the state of research surrounding FLT3 inhibitors.
good listener takes action immediately
Caring, open, interested in different aspects of my care.
Dr. Wander is the third oncologist I have seen and the only one I have felt cared about me.
Always listens carefully and provides feedback that makes sense. Will offer appointments with specialists as needed which is extremely helpful! I have questions prepared, and he gives me time to ask each one. Always excellent with follow through.
My appointment with Dr. Wander went well and efficiently.
This care provider is great. He always explains everything in detail and it's clear that he's read my file before the visit and is up to date on everything.
It is always a pleasure to see my oncologist. He has always helped me to understand every aspect of my journey through my breast cancer.
He is so very knowledgeable and always listens to my concerns. He is an excellent doctor.
he seems thorough
Seth has always been on time to my appointments, courteous, professional, and always answered all questions.